CARY, N.C., February 17, 2025—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, has been selected by Deciphera Pharmaceuticals, LLC as a distribution specialty pharmacy provider for ROMVIMZA (vimseltinib), approved on February 14, 2025, for the treatment of adult patients with symptomatic Tenosynovial Giant Cell Tumor (TGCT) for which surgical resection will potentially cause worsening functional limitation or severe morbidity.
Previously known as pigmented villonodular synovitis (PVNS) or giant cell tumor of the tendon sheath (GCT-S), TGCT is a locally aggressive neoplasm caused by dysregulation of the colony-stimulating factor 1 (CSF1) gene leading to over-expression of CSF1. Patients with TGCT can experience pain, swelling, impaired physical function, and limited range of motion, which negatively impacts quality of life.
“We are excited to work with Deciphera to help make this therapy available to patients with TGCT. With the approval of ROMVIMZA, patients now have a new option to treat their TGCT,” said Ela Lourido, vice president and general manager, Biologics by McKesson. “Biologics is honored to be a distribution partner for Deciphera Pharmaceuticals, LLC.”
Biologics by McKesson is committed to and recognized for its level of customer service as well as its innovative, high-touch, and multidisciplinary approach. Putting patients first in all they do, each team includes pharmacists with in-depth knowledge of therapies, experienced nurses, and financial counselors who are familiar with various financial assistance programs and organizations that help patients.
For more information about ROMVIMZA, including full prescribing information, please click here.